In addition to these new areas, Galenica has also signed an agreement to retain the majority of the laboratory premises it currently leases in the existing building. Thereafter, Galenica will lease a total of 4,000 m² of office space and laboratory premises as well as 700 m² of storage.

Galenica started at Medeon in 1999, with its current CEO Ronnie Wallin as one of the founders, and today has 70 employees. The company works with the formulation, production and quality control of pharmaceutical drugs and pharmaceutical-related products. It also develops its own pharmaceutical drugs.

“Galenica is a good example of how a company can grow and develop with the help of the environment offered by a science park. It makes it possible to start with an idea and leverage a network, incubator functions and other forms of support to gradually develop the company. With our current expansion of Medeon, in the form of a completely new building, it is naturally gratifying to see a company that was founded here becoming one of the first to move into the new building,” says Ulrika Hallengren, CEO of Wihlborgs.

“Galenica is growing and we need new and larger office premises as well as more laboratory space. We are currently spread across the park and look forward to working side by side in one office environment. The building being constructed by Wihlborgs is a good fit for us, in terms of size, and we are particularly pleased to remain at Medeon Science Park and to continue our growth journey,” says Ronnie Wallin, CEO of Galenica.

Medeon Science Park is located at the Forskaren 1 property in central Malmö and was founded in 1985. The new building which will be ready in autumn 2020, encompasses some 4,000 m² and is being certified to SGBC Gold.